Stock Detail
REPLIGEN CORPORATION
Sector: Biotechnology
Latest Quote @ Sat May 5 17:32:30 (15 min delayed)
| N/A |
N/A |
$8.48 |
-0.02 |
-0.24% |
|
Last Day's Data
| $8.48 |
$8.57 |
$0.00 |
0.00% |
0.00 |
$8.50 |
| $8.49 |
$8.42 |
114,981.00 |
266.64M |
215,374.00 |
17.63 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 8.64 |
8.56 |
8.49 |
8.41 |
8.34 |
Stock Profile
Repligen Corporation develops novel therapeutics for the treatment of diseases of the central nervous system. It sells Protein A products, which are used in the production of monoclonal antibodies and SecreFlo, a synthetic form of the hormone secretin, which is used as an aid in the diagnosis of certain pancreatic disorders. The company sells Protein A products to chromatography companies, diagnostics companies, biopharmaceutical companies, and laboratory researchers primarily through value-added resellers and distributors in the United States and internationally. It markets SecreFlo directly to gastroenterologists in the United States. The company also conducts drug development programs for diseases, such as schizophrenia, obsessive-compulsive disorder, bipolar disorder, and neurodegeneration. Repligen has a development agreement with the Stanley Medical Research Institute for a Phase 2 clinical trial of uridine in bipolar depression. The company was founded in 1981 and is based in Waltham, Massachusetts.
